Bubs Australia Limited Overview
Bubs Australia is a small-cap, Melbourne-based specialist in premium infant nutrition, built around goat-milk infant formula and complemented by A2 beta-casein bovine, organic grass-fed and a value-tier "Essential" range, plus CapriLac adult goat milk powder sold mainly in China. It owns its Victorian canning and blending operation (Deloraine Dairy) and sources Australian goat milk under a "farm-to-formula" model. Having entered the US during the 2022 formula shortage under FDA enforcement discretion, Bubs has repositioned from a China-dependent exporter into a US-led business: the US delivered A$65.8m, or roughly 59% of FY26 revenue of A$111.9m. On 7 September 2026 it secured permanent FDA authorisation for three formulas, making it, by its own account, the only Australian infant formula brand with permanent US access. The company is the #1 goat formula brand in Australia and on Amazon US, but remains marginally profitable, working-capital intensive and exposed to regulatory, tariff and freight shocks.
Company's own description. In its FY25 Annual Report, Bubs describes its principal activities as offering goat milk infant formula products, adult goat milk powder products, organic baby food and fresh dairy products, with the Group's principal activity being the manufacture and sale of infant formula, adult goat milk powder, fresh dairy products and organic baby food. Its current corporate boilerplate (FY26 announcements) positions it as a leading infant nutrition company offering organic and specialty formulas, including goat milk and grass-fed options, with a presence in Australia, the US and international markets including China. Its stated purpose (FY26 Results Presentation) is to provide clean nutrition products that give parents peace of mind and support lifelong wellbeing for babies; its mission (Strategy Update, Mar 2026) is to make naturally gentle, clean nutrition the first choice for modern parents—recognisably Australian and trusted globally.
Independent characterisation. Bubs is a branded, product-led consumer staples business operating a partially vertically integrated model. It controls the final manufacturing stages (blending and canning at its Victorian facility, Deloraine Dairy, acquired 2019), procures goat milk from Australian farms (herd expanded >70% in FY26), and uses third-party partners for base powders, non-dairy ingredients, logistics and in-market distribution. Revenue is almost entirely product sales recognised at the point of transfer, net of trade spend, rebates and marketing contributions; there is no subscription or licensing revenue of note, and only immaterial services (contract canning, A$0.6m in FY24, nil in FY25).
Revenue model mix (FY25 Annual Report, Note B2).
FY26 product-level disaggregation was not disclosed in the results materials reviewed.
Value chain position. Per the Strategy Update (Mar 2026), the chain runs from milk collection on Australian farms, through spray drying (partner-supplied base powder), blending of functional ingredients and canning with tin-level traceability (Bubs-controlled), to integrated global logistics and omnichannel consumer engagement. Management is explicitly migrating from a single-source Australian supply chain to a multi-partner global network with market-proximate manufacturing, described as asset-light (Strategy Update, Mar 2026).
Customer types and channels.
USA: National and regional retailers (Target, Walmart, Kroger, H-E-B, Meijer, Sprouts, Giant Eagle, Sam's Club) and e-commerce (Amazon, where Bubs is the #1 goat infant formula); 10,000+ doors across all 50 states by July 2026 (FY26 Presentation).
China: Cross-border e-commerce (Tmall Global, JD.com, Douyin) and online-to-offline (O2O) mother-and-baby stores (1,800+ stores in FY26; entry to KidsWant, China's largest mother & baby chain, in late June 2026).
Australia: Woolworths, Coles, Metcash, pharmacy (e.g., My Chemist/Chemist Warehouse group), specialty, Amazon Australia.
Rest of World: Distributor-led markets — Japan, Vietnam, Malaysia, Saudi Arabia, Singapore, Cambodia; Canada entry flagged in FY26.
Concentration: Two customers each exceeded 10% of FY25 revenue, totalling A$29.8m (one customer, A$20.0m, in FY24) (FY25 Annual Report).
End-markets served. Infant milk formula (stage 1–2), toddler/growing-up milk, adult goat milk powder (China-centric), and historically organic baby food (Australian food portfolio discontinued in 1H FY26 per company commentary reported by Stockwirex).
Strategy
Strategic evolution. In 2023 the reconstituted board set a five-pillar plan: (1) USA as the growth engine; (2) China reset; (3) portfolio optimisation; (4) "sweat the assets" (Deloraine utilisation); and (5) working capital discipline (FY25 AR). Under Joe Coote, this was superseded by the 2030 strategy unveiled at the Strategy Update Day on 26 March 2026.
2030 strategy architecture (Strategy Update, Mar 2026; FY26 Presentation).
Purpose: Clean nutrition delivering peace of mind for parents and lifelong wellbeing for babies.
Values: Transparency, Courage, Collaboration, Inspiration.
Pillar 1 – Activate Brand and Consumer: Evolve the brand to a "naturally gentle, backed by science, of Australia" positioning; build intimacy with "Zillennial" urban, high-income, digitally engaged parents aged 25–40 (repeat purchase rates of 28–54%); data-driven digital marketing using marketing-mix modelling, retail media (Amazon DSP, Walmart Connect, Target Roundel) and social (Meta, TikTok, Reddit).
Pillar 2 – Build a Winning Portfolio: Profitable growth across Strategic markets (USA, China, Australia), Growth markets (Canada, Mexico, Vietnam) and Partner markets (Japan, Cambodia, Middle East); goat and bovine renovations; optionality for adjacencies (supplements, RTD, snacks, personal care), private label, manufacturing diversification and partnerships. Product ladder: infant formula (core entry) → infant supplements → toddler nutrition → snacks → adult nutrition (adjacent brand).
Pillar 3 – Connect Farm to Formula: Operational excellence; capacity expansion based on optimal scale and partner model; technology for traceability; shift from single-source to global multi-partner network with market-proximate manufacturing.
Enablers: Performance culture, Transformation Office (PMO) with stage-gated capital allocation and defined payback thresholds, innovation pipeline, strategic partners, digital and AI adoption.
Market ambitions. USA: top-3 premium natural IMF and top-2 goat IMF brand; expand in under-penetrated regions (e.g., Northeast), club, drug and specialty; relaunch website with e-commerce, CRM and education platform; enter super-premium. China: expand general trade including China-label (SAMR) products via mother-and-baby chains (e.g., KidsWant), invest in lower-tier cities, extend into supplements. Australia: drive trial in goat and organic, increase premium mix, improve in-store and e-commerce execution.
Initiatives delivered or in progress (last 24 months).
Financial targets and guidance history.
Medium-term framework (Strategy Update): Double-digit revenue growth with operating leverage; revenue and margin growth to outpace working capital growth; positive operating cash flow; capital-light balance sheet through the cycle.
Products & Services
All products sit within the single reported segment. Pricing is not publicly disclosed in filings; Bubs positions as premium in all markets, with the Essential range as its value-tier entry.
Historic US portfolio: All six Bubs infant formula products entered the US in June 2022 under enforcement discretion (Q4 FY22 4C). The permanent authorisation covers three SKU families (Goat, 365 Day Grass Fed, Essential); the NIFS lodged June 2025 covered these three.
Product Portfolio
| Product / brand | Description & key attributes | Target customer | Launch / latest | Markets | Notes |
|---|---|---|---|---|---|
Bubs Goat Milk Infant Formula ("Easy-Digest") | Goat-milk based infant formula (stages 1–3 historically); positioned on gentle digestion; Clean Label Project Purity Award five years running; certified pesticide-free | Parents seeking gentle-digestion, clean-label formula; combo-feeding and early switchers | Goat range launched c.2013; packaging refresh FY25 | Australia, US, China (CBEC/O2O), ROW | Flagship; #1 goat formula in Australia (53.5% sub-category share FY25), #1 goat IMF on Amazon US; covered by permanent FDA authorisation (Sep 2026) |
Bubs 365 Day Grass Fed (US name) / Bubs Organic Grass-fed (AU) | Bovine formula from grass-fed / certified organic milk | Organic/natural-seeking parents | Organic formula launched c.2017 per timeline | US, Australia, ROW | Covered by permanent FDA authorisation |
Bubs Essential(s) | Competitively priced bovine formula extending into mainstream segment | Value-conscious parents | Launched FY25 (Australia, ranged at Woolworths) | Australia, US | Covered by permanent FDA authorisation |
Bubs Supreme A2 Beta-Casein Protein | Bovine formula using A2 beta-casein protein milk | Premium A2-seeking parents (China and Australia) | Launched c.FY22 | China (CBEC), Australia, ROW | China inventory overhang cleared in FY24; key FY25 China growth driver |
Bubs toddler / growing-up milk | Toddler milk drinks (goat and bovine) | Parents of 1–3 year olds | Ongoing; China "Kids" growing-up extension launched FY26 | Australia, China, ROW | Lifecycle extension per 2030 strategy |
CapriLac adult goat milk powder | Adult goat milk powder; China label version launched FY26; offline expansion into ~100 premium retail outlets | Adults/families, primarily in China | Acquired with NuLac Foods 2017 | China (Tmall Global), Australia | Won Tmall Global category award (FY26); adult revenue A$12.4m in FY25 |
Bubs Organic baby food (pouches, cereals) | Organic baby food range | Infants on solids | Long-standing; Australian food portfolio discontinued 1H FY26 | Australia (historically), ROW | "Nutritional products" revenue A$1.1m FY25 |
New formats (pipeline) | Powder sachets and ready-to-drink (RTD) formats; infant supplements | Convenience/premium buyers | Flagged FY26 Strategy Update | China (first), US adjacencies | Part of "Build a Winning Portfolio" pillar |
Club pack | Bulk format launched at Sam's Club | Bulk-buying US consumers | FY26 | US | Retail execution initiative |
Contract manufacturing / private label (prospective) | FDA variant application lodged 9 Sep 2026 to pursue contract manufacturing | US retailers/brands | Prospective | US | Subject to further regulatory, technical and commercial milestones |
Fresh dairy | Fresh goat dairy products (legacy NuLac business) | Australian consumers | Legacy | Australia | Referenced in FY25 principal activities; revenue immaterial/not separately disclosed |
Financial Narrative
Income statement: notes and sources
Sources: FY25 Annual Report five-year summary and statements (FY22–FY25); FY26 Results Presentation; FY23/FY24 results releases; FY22 annual results. FY24 and FY25 EPS in cents derived from NPAT and weighted shares (832.3m and 893.0m); FY26 EPS derived using ~893m shares. FY22/FY23 EPS as reported in FY25 AR (rounded to whole cents).
Margins and growth
Derived from 6.1. Underlying margins use "as reported at the time" for FY22–FY24, restated for FY25. Opex ratios per company (FY25 AR; FY26 Presentation; FY25 shown as 45% on FY26 basis, 44% on FY25 AR basis).
Revenue CAGR (derived): FY22–FY26 four-year CAGR ≈ 5.8% (distorted by the FY22 China/daigou and Operation Fly Formula spike); FY23–FY26 three-year CAGR ≈ 23.0%. Management cites a 3-year CAGR of 26% using FY26 guidance of A$120–125m that was subsequently missed (Strategy Update).
FY26 earnings bridge
Total tariff-related costs were A$2.6m (H1 A$0.3m, H2 A$2.3m), of which A$1.0m of non-AU tariffs is excluded from underlying EBITDA. Item-by-item arithmetic as presented sums to ~A$5.5m versus the stated A$5.3m; the difference is presumably rounding or presentation and is flagged rather than resolved.
Balance sheet: notes and sources
Sources: FY25 AR statements; FY26 Results Presentation; Q4 FY22 4C (FY22 cash, pre-A$63m raise); FY24 opening balances (FY23 cash and equity). FY23 borrowings derived from FY24 cash flow (closing A$5.28m less A$4.8m drawn plus A$1.8m repaid). FY26 net current assets derived (current assets A$60.5m less current liabilities A$27.7m). FY26 debt: A$10.0m drawn under bank facilities with A$10.0m undrawn; NAB facility extended to 31 Aug 2027. Goodwill stands at only A$0.57m after cumulative impairments of A$90.0m against A$90.6m gross goodwill.
Cash flow
FY26 capex shown as total investing cash flow. FY22 raise of A$63m was announced and largely settled around July 2022 (straddling FY22/FY23). FY24 raise of A$17.4m (net A$15.7m after costs).
Ratios (derived)
ROIC and cash conversion cycle not computed due to insufficient disclosed detail.
Commentary on trends, inflections and drivers
Three regimes. The five-year record divides into (i) a volatile China-led boom and bust (FY21–FY23), (ii) a turnaround under new governance (FY24–FY25), and (iii) a growth-investment year disrupted by external shocks (FY26). FY22 revenue of A$89.3m was flattered by a five-fold increase in corporate daigou revenue in China and two Operation Fly Formula flights in June 2022. The collapse in FY23 (revenue −32.7%, China −73%) reflected inventory overhang with the former exclusive China distributor (Alice/Willis), resulting in A$36.2m of non-cash impairments against Deloraine and NuLac assets, negative gross profit due to inventory provisions, and a statutory loss of A$108.4m.
Turnaround. FY24 restored a 48.6% gross margin (partly aided by A$20.6m of inventory provision reversals) and grew revenue 33% as the US scaled. FY25 was the inflection: opex-to-revenue fell from 73% to 44%, operating cash flow turned positive at A$6.1m (three consecutive positive quarters), and Bubs recorded its maiden statutory profit of A$5.5m, aided by A$3.6m of legal credit recoveries and a A$1.3m insurance receipt that were excluded from underlying EBITDA of A$0.6m.
FY26 disruption. Revenue grew 9.2% to A$111.9m, short of the A$120–125m guidance reiterated in February and March 2026, after H2 disruption from a "regulatory reset" (new labelling/registration requirements that paused trading in Vietnam and Singapore and slowed China customs clearance), US tariffs, and airfreight to restore US stock. Reported gross margin compressed eight points to 39.8%, while underlying gross margin held at 46.8%. Underlying EBITDA rose to A$5.3m, demonstrating operating leverage when one-offs are excluded, but reported EBITDA was −A$1.8m and NPAT −A$4.6m. The A$16.2m inventory rebuild (A$20.1m → A$36.3m) drove a A$15.1m operating cash outflow, cutting cash to A$9.4m and requiring A$10.0m of bank drawings. Management states the restocking is complete and NWC/sales has normalised at 31.7%.
Quality of earnings. Investors should weight underlying measures cautiously: in each of FY25 and FY26, items excluded from underlying EBITDA were material relative to the result (FY25: A$4.9m of credits removed; FY26: A$7.1m of costs added back). The FY25 accounts were prepared on a going-concern basis with an explicitly disclosed material uncertainty tied to FDA approval; that key assumption has now been satisfied (Sep 2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Market revenue (AUD Mn)
| Market revenue (AUD Mn) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
USA | 23.9 | 35.0 | 53.1 | 65.8 |
China | 13.6 | 17.3 | 21.1 | 21.4 |
Australia | 17.4 | 21.6 | 19.8 | 18.3 |
Rest of World | 5.3 | 5.9 | 8.5 | 6.4 |
Total | 60.1 | 79.7 | 102.5 | 111.9 |
Market YoY growth (%)
| Market YoY growth (%) | FY24 | FY25 | FY26 |
|---|---|---|---|
USA | 46 | 52 | 24 |
China | 27 | 22 | 1 |
Australia | 24 | -8 | -7 |
Rest of World | 11 | 44 | -25 |
Group | 33 | 29 | 9 |
Share of revenue (%)
| Share of revenue (%) | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
USA | 40 | 44 | 52 | 59 |
China | 23 | 22 | 21 | 19 |
Australia | 29 | 27 | 19 | 16 |
Rest of World | 9 | 7 | 8 | 6 |
Income Statement and Per-Share Data
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 89.3 | 60.1 | 79.7 | 102.5 | 111.9 |
Gross profit (AUD Mn) | 28.9 | -9.4 | 38.7 | 49.1 | 44.5 |
Underlying gross profit (AUD Mn) | — | — | — | 49.7 | 52.3 |
Operating expenses (AUD Mn) | — | — | — | 46.5 | 48.8 |
EBIT / operating profit (AUD Mn) | -10.4 | -107.6 | -21.2 | 4.5 | -3.4 |
Reported EBITDA (AUD Mn) | -7.8 | -105.2 | -19.7 | 5.2 | -1.8 |
Underlying EBITDA as reported at the time (AUD Mn) | 4.8 | -34.4 | -19.7 | 0.6 | 5.3 |
Underlying EBITDA latest restated basis (AUD Mn) | — | -69.1 | -20.3 | 1.2 | 5.3 |
Pre-tax income (AUD Mn) | -11.3 | -107.5 | -20.5 | 5.5 | — |
Net income after tax (AUD Mn) | -11.4 | -108.4 | -21.0 | 5.5 | -4.6 |
Basic EPS (A$ cents) | -2 | -15 | -2.5 | 0.6 | -0.5 |
Diluted EPS (A$ cents) | -2 | -15 | -2.5 | 0.6 | -0.5 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric (%) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Revenue growth (%) | 127.2 | -32.7 | 32.6 | 28.7 | 9.2 |
Gross margin (%) | 32.4 | -15.6 | 48.6 | 47.8 | 39.8 |
Underlying gross margin (%) | — | — | — | 48.5 | 46.8 |
Operating (EBIT) margin (%) | -11.7 | -178.9 | -26.5 | 4.4 | -3.0 |
Reported EBITDA margin (%) | -8.7 | -175.1 | -24.7 | 5.1 | -1.6 |
Underlying EBITDA margin (%) | 5.4 | -57.2 | -25.5 | 1.2 | 4.7 |
Net margin (%) | -12.8 | -180.4 | -26.3 | 5.4 | -4.1 |
Opex to revenue (%) | — | — | 73 | 45 | 44 |
Bridge Item Details
| Bridge item | FY26 |
|---|---|
Reported EBITDA | -1.8 |
Add: USA airfreight (H1 1.9, H2 1.1) | 3.0 |
Add: Regulatory reset (all H2) | 3.9 |
Add: USA non-AU tariff | 1.0 |
Less: Alice & Willis settlement credit | -0.8 |
Add: Restructure costs | 0.2 |
Underlying EBITDA (company stated) | 5.3 |
Balance Sheet and Margin Analysis (%)
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Total assets (AUD Mn) | — | — | 66.8 | 57.2 | 72.2 |
Cash and equivalents (AUD Mn) | 16.3 | 26.1 | 17.5 | 17.4 | 9.4 |
Inventories (AUD Mn) | — | — | 28.2 | 20.1 | 36.3 |
Short-term borrowings (AUD Mn) | — | 2.3 | 5.3 | 0.0 | 10.0 |
Long-term borrowings (AUD Mn) | — | 0.0 | 0.0 | 0.0 | 0.0 |
Lease liabilities (AUD Mn) | — | — | 1.7 | 1.0 | — |
Net debt excl. leases (AUD Mn) | — | -23.8 | -12.2 | -17.4 | 0.6 |
Total equity (AUD Mn) | — | 41.7 | 36.9 | 42.5 | 39.0 |
Goodwill and intangibles (AUD Mn) | — | 1.2 | 1.2 | 1.2 | — |
Net current assets (AUD Mn) | — | — | 31.1 | 37.0 | 32.8 |
Net working capital, company definition (AUD Mn) | — | — | 24.3 | 23.2 | 35.5 |
NWC to sales (%) | — | — | 30.5 | 22.6 | 31.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
Operating cash flow (AUD Mn) | — | -46.5 | -26.3 | 6.1 | -15.1 |
Capex incl. intangibles (AUD Mn) | — | — | -0.2 | -0.1 | -1.2 |
Free cash flow (AUD Mn) | — | — | -26.5 | 6.0 | -16.3 |
Financing cash flow (AUD Mn) | — | — | 18.0 | -6.0 | 8.3 |
Equity raised gross (AUD Mn) | 63.0 | 0.0 | 17.4 | 0.0 | 0.0 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY24 | FY25 | FY26 |
|---|---|---|---|
ROE (%, on average equity) | -53.4 | 13.9 | -11.3 |
ROA (%, on average assets) | — | 8.9 | -7.1 |
Current ratio (x) | 2.09 | 3.65 | 2.18 |
Debt to equity (x, excl. leases) | 0.14 | 0.00 | 0.26 |
Net debt to underlying EBITDA (x) | — | — | 0.11 |
Interest coverage, EBIT/interest (x) | — | 9.2 | — |
Asset turnover (x) | — | 1.65 | 1.73 |
Region revenue (AUD Mn)
| Region revenue (AUD Mn) | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
USA | 8.0 | 23.9 | 35.0 | 53.1 | 65.8 |
China | 49.4 | 13.6 | 17.3 | 21.1 | 21.4 |
Australia | 14.5 | 17.4 | 21.6 | 19.8 | 18.3 |
Rest of World | 17.4 | 5.3 | 5.9 | 8.5 | 6.4 |
Total | 89.3 | 60.1 | 79.7 | 102.5 | 111.9 |
Region revenue (AUD Mn) (Half-Yearly)
| Region revenue (AUD Mn) | 1H FY24 | 1H FY25 | 1H FY26 |
|---|---|---|---|
USA | 18.2 | 23.2 | 34.2 |
China | 7.1 | 10.2 | 7.5 |
Australia | 11.7 | 10.5 | 9.6 |
Group | 39.4 | 48.5 | 55.5 |
Share price (AUD)
| Share price (AUD) | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.435 | 0.595 | 0.180 | 0.130 | 0.170 |
Recent Price Points Details
| Recent price points (AUD) | Date | Price |
|---|---|---|
AGM | 20 Nov 2025 | 0.150 |
Q2 update | 30 Jan 2026 | 0.130 |
1H results | 27 Feb 2026 | 0.120 |
Strategy Day | 26 Mar 2026 | 0.105 |
Trading downgrade | 29 May 2026 | 0.094 |
Pre-FDA halt | 4 Sep 2026 | 0.100 |
FDA approval close | 7 Sep 2026 | 0.135 (intraday 0.145) |
52-week high (approx.) | — | ~0.165 |
Valuation Multiples
| Multiple | Bubs (FY26) | Peer reference |
|---|---|---|
Market capitalisation | ≈A$116m | — |
Enterprise value (mkt cap + A$10.0m debt − A$9.4m cash; excl. leases) | ≈A$117m | — |
P/E | n.m. (loss) | — |
EV/Sales | ≈1.0x | — |
EV/Underlying EBITDA (A$5.3m) | ≈22x | — |
P/B (equity A$39.0m) | ≈3.0x | FNArena showed P/B 3.78x (Mar 2026 data) |
Analyst Ratings & Targets
| Broker | Date | View / target | Notes |
|---|---|---|---|
Bell Potter | 8 Sep 2026 | Price target raised from A$0.135 to A$0.19 | Post-FDA |
Shaw and Partners | Mar 2026 | — | Praised 1H EBITDA beat |
TipRanks aggregate | Pre-Sep 2026 | Three buy ratings; average target ~A$0.13 | Pre-FDA |
Debt (AUD Mn)
| Debt (AUD Mn) | FY24 | FY25 | FY26 |
|---|---|---|---|
Drawn bank borrowings (AUD Mn) | 5.3 | 0.0 | 10.0 |
Undrawn facilities (AUD Mn) | 4.7 | 10.0 | 10.0 |
Analyst Conclusions
Management guidance (27 Aug 2026). Qualitative only for 1H FY27: improved momentum as the business adapts to the new regulatory and US tariff environment; positive revenue growth with mixed regions (USA continued strong growth; China growth from distribution and marketing; Australia continued marketing investment; ROW mixed but product flows improving); gross margin expected to rebound; working capital positioned for growth; continued brand investment; FDA process now finalised.
Bell Potter's 19c target implies ~45% upside from 13c. Management's framework targets double-digit revenue growth with operating leverage.
Bull case
-
Regulatory moat now permanent: With FDA authorisation secured, the US (59% of revenue, +24% in FY26 even while supply-constrained) can compound as 10,000+ doors mature and retailer conversations broaden to private label.
-
Margin rebound is mechanical: Underlying gross margin was 46.8% versus 39.8% reported; if airfreight (A$3.0m) and regulatory reset (A$3.9m) costs do not recur, reported EBITDA could move toward the A$5–10m range on modest growth.
-
Inventory investment done: The A$16.2m restock is complete; normalised NWC/sales of 31.7% means future growth should be less cash-hungry, supporting positive operating cash flow.
Bear case
-
Recurring "one-offs": Freight, tariffs and regulatory costs recurred across quarters; Bubs' Australia-to-US supply chain is structurally exposed, and underlying EBITDA may overstate sustainable earnings.
-
Balance sheet limits: A$9.4m cash and A$10m drawn debt constrain marketing versus multinationals; any stumble could force dilutive equity (raises of A$63m in 2022 and A$17.4m in 2023).
-
Execution and credibility: FY26 guidance was cut sharply three months after reaffirmation; leadership churn is high; Australia continues to lose ground and China growth has stalled.
Key catalysts and monitorables (next 12 months)
-
1H FY27 results (Feb 2027) and quarterly 4Cs (Oct 2026, Jan 2027, Apr 2027, Jul 2027): gross margin recovery toward 45%+ and positive operating cash flow.
-
US scan data: velocity per store across 10,000+ doors; goat share versus Kendamil/Kabrita.
-
Outcome of the FDA variant application and any announced private-label/contract-manufacturing agreement.
-
US tariff policy on Australian dairy imports; freight normalisation.
-
Vietnam relaunch (1H FY27) and Singapore resumption; China customs normalisation; KidsWant sell-through.
-
Australian share recovery after H2 FY26 marketing step-up.
-
AGM (expected Nov 2026): board renewal, remuneration votes, potential FY27 numeric guidance.
-
NAB facility renewal ahead of 31 Aug 2027; capital management decisions.
Concluding analyst verdict
Bubs Australia has emerged from a near-death sequence — a China channel collapse, A$108m statutory loss and a bitter governance war in FY23 — into a credible, US-led specialist infant nutrition brand. The September 2026 permanent FDA authorisation is the single most important event in the company's listed history: it converts a temporary, shortage-era foothold into a durable licence to operate in the world's most profitable premium formula market, removes the going-concern uncertainty disclosed in the FY25 accounts, and opens a private-label option that could use the Victorian plant's idle third shift.
Yet the FY26 result shows how far Bubs remains from being a robust earnings compounder. A business generating A$112m of revenue absorbed nearly A$8m of freight, regulatory and tariff costs, swung to a A$4.6m net loss, and burned A$15m of operating cash to rebuild inventory, leaving only A$9.4m of cash. Guidance credibility was damaged by a mid-year downgrade, the home market is shrinking, China is flat, and leadership has turned over repeatedly. Underlying EBITDA of A$5.3m (4.7% margin) compares with a2 Milk's ~15% margin at roughly eighteen times the scale, underscoring the operating-leverage gap Bubs must close.
At roughly A$116m market capitalisation (≈1.0x EV/sales, ≈22x EV/underlying EBITDA), the market is pricing a partial — not full — normalisation. The investment case now hinges on execution rather than regulation: demonstrating that reported gross margins return to the mid-40s, that the expanded US footprint produces rising velocity rather than one-off pipeline fills, and that growth can be funded internally. If 1H FY27 delivers positive operating cash flow and reported EBITDA consistent with underlying trends, a re-rating toward broker targets is plausible. Absent that, the stock remains a high-risk, catalyst-driven small cap. Verdict: speculative, improving fundamentals with materially de-risked regulatory position; balance-sheet and execution risk keep it a watch-and-verify position pending 1H FY27 evidence.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Education |
|---|---|---|---|
Joe Coote | CEO (from 28 Jul 2025); Managing Director (board from Sep 2025) | Former CEO of Darigold (fourth-largest US dairy co-operative); ~12 years at Fonterra in senior roles including President across US, Asia and ANZ; 20+ years FMCG/dairy/infant nutrition; returned to Australia after ~15 years abroad | — |
Chris Rowe | Chief Financial Officer | In role by Aug 2026 (co-hosted FY26 results); appointment date not disclosed in sources reviewed | — |
Naomi Verloop | Former CFO (appointed 10 Feb 2025) | Presented at Mar 2026 Strategy Day; departure date not disclosed in sources reviewed | — |
Richard Paine | Chief Operating Officer | Long-serving; interim CEO May–Aug 2023 | — |
Jasmin Manner | President – US | Leads largest market | — |
Jackie Lin | General Manager – China | Leads China business | — |
Chris Lotsaris | General Manager – Australia and ROW | — | — |
Annie Chen | Chief Marketing Officer | Leads global brand refresh | — |
Kathryn O'Hehir | General Manager – Corporate Services | Leads Transformation Office | — |
Peter Cope | General Counsel (from 18 Jan 2022) and Company Secretary (from 1 Jan 2025) | Ex-Hall & Wilcox, AusNet Services, Murray Goulburn, Melbourne Airport; Chartered Accountant (ex-Deloitte) | BSc, BCom, LLB, LLM (University of Melbourne) |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Appointed | Independence | Background |
|---|---|---|---|---|
Paul Jensen | Independent Chair (from Sep 2025); previously Chair of Audit & Risk Committee | 20 Mar 2023 | Independent | 20+ years as professional director; prior NED roles include Hunter Hall Global Value, Sandon Capital, RHG, WAM Capital, Foodco Group, Forty Winks; Director of Australian Made Campaign, Alterra, GNS Wholesale; executive career incl. Lloyds Bank; BCom (Victoria University of Wellington); FAICD |
Joe Coote | Managing Director & CEO | Board from Sep 2025 | Executive | See above |
Steve Lin | Non-Executive Director | 18 Apr 2019 | Non-independent (represents C2 Capital, largest holder) | Managing Partner, C2 Capital Partners; boards of Stella & Chewy's, Petcurean, KDC/ONE; ex-Morgan Stanley, Goldman Sachs; economics degree, Harvard College; based in US |
Lori Tauber Marcus | Independent Non-Executive Director | 21 May 2026 | Independent | US-based; 24 years at PepsiCo; former EVP and Chief Global Brand & Product Officer at Keurig; boards include Fresh Del Monte Produce, Primo Water, Phunware |
Directors' Remuneration
| KMP (AUD) | Salary & fees | STI | Super | Share-based | Other (leave/LSL) | Total FY25 | Total FY24 |
|---|---|---|---|---|---|---|---|
Reg Weine (CEO/MD to 28 Jul 2025) | 738,629 | 676,710 | 29,932 | 343,619 | 67,560 | 1,856,450 | 990,640 |
Richard Paine (COO) | 409,360 | 213,037 | 29,932 | 20,351 | 34,813 | 707,493 | 548,708 |
Naomi Verloop (CFO from Feb 2025) | 136,258 | 76,233 | 12,472 | 18,986 | 12,413 | 256,362 | 0 |
Aaliyah Nyathi (Interim CFO Oct 2024–Feb 2025) | 98,200 | 0 | 9,669 | 0 | 6,354 | 114,223 | 0 |
Robin Johnston (CFO to Sep 2024) | 66,277 | 0 | 6,867 | 0 | 6,872 | 80,016 | 355,046 |
Katrina Rathie (Chair) | 206,000 | 0 | 23,690 | 0 | 0 | 229,690 | 232,696 |
Paul Jensen (NED) | 149,300 | 0 | 0 | 0 | 0 | 149,300 | 141,525 |
Steve Lin (NED) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Major Shareholders
| Holder | Shares | % | Source / date |
|---|---|---|---|
C2 Capital Partners (Alibaba-anchored PE; represented by Steve Lin) | 76,288,510 | 8.54 | FY25 AR (30 Jun 2025) |
Paul Jensen (Chair, via Taranaki Holdings) | ≈3,630,890 (derived) | ≈0.4 | 500,000 at 30 Jun 2025 + 630,890 (Sep 2025) + 1,000,000 (Mar 2026) + 1,500,000 (31 Aug–1 Sep 2026, ~A$130,500 at 8.55–8.7c) |
Richard Paine (COO) | 561,967 | <0.1 | FY25 AR |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap | Positioning vs Bubs |
|---|---|---|
The a2 Milk Company (ASX: A2M) | A2 bovine IMF (Australia, China, US) | Far larger (NZ$1.97bn FY26 revenue); vertically integrating (a2 Pōkeno); direct rival to Bubs Supreme |
Abbott (Similac) | US mass and premium IMF | US category leader; 2022 Sturgis recall triggered the shortage that opened the US to Bubs |
Reckitt / Mead Johnson (Enfamil) | US mass and premium | Major US incumbent with WIC exposure |
Nestlé (Gerber, NAN, illuma) | Global, US, China, Australia | Global scale and science resources |
Danone (Aptamil, Karicare incl. goat variant) | Australia, China, global | Leading Australian/China premium player; Karicare Goat competes directly |
Perrigo (store brands) | US private label | Relevant if Bubs pursues private label |
Kendal Nutricare (Kendamil, including goat) | US premium/natural, goat | Fast-growing UK whole-milk/goat brand in US |
Ausnutria (Kabrita goat) | Goat IMF in US, China | Leading global goat specialist |
Dairy Goat Co-operative NZ / Nuchev (Oli6) | Goat IMF Australia/China | Goat category rivals |
ByHeart, Bobbie | US premium natural (FDA-registered US makers) | Venture-backed US challengers in premium natural |
Bellamy's Organic (Mengniu) | Organic IMF Australia/China | Competes with Bubs Organic |
Peer Comparison FY2026
| Metric | Bubs Australia (FY26) | a2 Milk Company (FY26) |
|---|---|---|
Revenue | A$111.9m | NZ$1,974.9m |
Revenue growth | 9.2% | 12.4% |
Gross margin | 39.8% (underlying 46.8%) | 47.7% |
EBITDA margin | -1.6% (underlying 4.7%) | 14.4% (underlying 15.6%) |
US growth | 24% | 28.6% (USA segment) |
Recent Developments
--



